Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6544
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study ; volume:11 ; number:1 ; day:29 ; month:1 ; year:2022 ; pages:113-127 ; date:3.2022
Cardiology and therapy ; 11, Heft 1 (29.1.2022), 113-127, 3.2022
- Urheber
-
Houchen, Emma
Loefroth, Emil
Schlienger, Raymond
Proudfoot, Clare
Corda, Stefano
Saha, Sibasish
Satwase, Sarvesh K.
Studer, Rachel
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40119-021-00252-4
- URN
-
urn:nbn:de:101:1-2022061106034758705686
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Houchen, Emma
- Loefroth, Emil
- Schlienger, Raymond
- Proudfoot, Clare
- Corda, Stefano
- Saha, Sibasish
- Satwase, Sarvesh K.
- Studer, Rachel
- SpringerLink (Online service)
Ähnliche Objekte (12)
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
![Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung